Emerging treatments
Cabozantinib
Cabozantinib, a multiple receptor tyrosine-kinase inhibitor that inhibits tumor growth and angiogenesis, has been found to significantly improve progression-free survival compared to placebo in patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors.[67]
Use of this content is subject to our disclaimer